By blocking endogenous miR-185 and 342 in prostate cancer cells, both miR-185 and 342 inhibitors increased SREBP-1, SREBP-2 and their downstream gene expression (Fig. 1C). This evidence concerns the gene SREBF2 and Familial prostate cancer.